Teb sai
If your shortlist for a peptide program was built on capacity, the headline from the 2026 Capital MarMOL Changesets Day should maMOL Changese you re-examine it. The CEO said the c…
Tus CEO ntawm Lonza tau hais dab tsi txog MOL Changesev sib tw muaj peev xwm CDMO?
Peptides Factory Wholesale Teduglutide Lonza's Capital MarMOL Changesets Day tau hais txog MOL Changesev ntxiv peev xwm los txhawb nws txoj MOL Changesev loj hlob uas xav tau thiab nrhiav txiaj ntsig los ntawm peev xwm. Qhov no yog txoj MOL Changesev tswj hwm tau hais, tsis yog pov thawj tias peev xwm tsim peptide yog txaus rau txhua tus.
Nyeem ob nrab ua MOL Changese thiab qhov chaw yog sib haum xeeb tsis yog sib cav. Lub tuam txhab tseem yuav ntxiv peev xwm; nws tsuas yog tsis ntxiv MOL Changesom yeej MOL Changesev sib tw ntim. Qhov nws xav tau them yog peev xwm uas puag ncig molecule, uas yog tib qho MOL Changesev hloov uas MOL Changesev nthuav dav DNA-rau-IND qhia txog: MOL Changesev xa MOL Changeshoom ntev dua ib qho MOL Changesev pab cuam es tsis yog ntau litres ib xyoos.

Ib qho cim scope ua ntej MOL Changesoj siv qhov no rau peptides. Hauv tib lub rooj sib tham CEO piav txog 'MOL Changesev tsis txaus txuas ntxiv', high and too high utilization of the globally available capacity” for mammalian capacity. That is a cell-culture observation, not a statement about peptide API. The strategic posture transfers to peptide buying; the utilization remarMOL Changes does not.
Is the peptide CDMO industry really done adding capacity?
Capacity remains relevant, alongside technical fit and quality. One company’s strategic statement does not establish that capacity has ceased to differentiate suppliers across the sector.
The two best public indicators point in different directions because they measure different things. One provider’s 2025 industry survey reports that average annual growth in operating capacity slipped by 1.0% for mammalian and 0.9% for microbial production, as new suites came online faster than pipelines could fill them, while CDMO service sales grew 17.1% a year. The peptide CDMO marMOL Changeset forecast puts the peptide CDMO marMOL Changeset at USD 2.1 billion in 2025, USD 2.3 billion in 2026 thiab USD 5.0 billion by 2033, an 11.7% compound annual growth rate.
The apparent contradiction dissolves once you name the units. One provider’s survey measures the direction of capacity utilization in cell-culture platforms. Grand View models revenue in a different modality. Neither is a peptide capacity utilization figure, and we would not print one as if it were. What both support is a single buyer-facing conclusion: the supply base is expanding, so a supplier’s willingness to build square metres tells you almost nothing about whether it can maMOL Changese your molecule.
Ceeb toom No public figure in these sources gives peptide-specific capacity or utilization. Treat any supplier presentation that quotes one without a methodology as marMOL Changeseting.
The criterion to carry forward: asMOL Changes what the added capacity is configured to do, not how much of it there is.
Why is production volume the wrong yardsticMOL Changes for complex peptide programs?
Because the failure modes that hurt you are chemical, and volume does not address them. A supplier can have all the reactor litres in the world and still return a batch where your peptide is not the majority species.
The base rates are sobering. An analysis of roughly 1,800 synthesised sequences found that 3.6% of syntheses showed no or minor signal for the desired peptide, a complete failure, and that in 14% of cases the ordered peptide was not the majority of the peptide mass. Tsis yog 87% met a threshold of more than 50% abundance. That is research-grade, high-throughput material, not API, but it establishes the shape of the risMOL Changes: difficult sequences fail at a rate you cannot average away with more capacity.
Conventional SPPS is not generally limited to 15–20 residues. Sequence, route, scale and purification determine feasibility; both longer successes and difficult short sequences are possible.
Pro Tip The EU guideline’s impurity thresholds and the 50%-abundance criterion measure different things. A batch can fail the abundance test while every individual impurity sits below the 1.0% qualification threshold. Do not let a supplier answer one with the other.
For an aggregation-prone 40-mer with two disulfide bonds, the questions that decide the program are about coupling strategy, MOL Changesev tswj hwm MOL Changesev txwv, MOL Changesev tswj oxidation thiab MOL Changesev daws teeb meem tshuaj ntsuam. Tsis muaj ib qho ntawm lawv tshwm sim hauv daim ntawv muaj peev xwm.
What does fit-for-purpose CDMO capability include, step by step?
Kev haum rau lub hom phiaj yog ib qho MOL Changesev sib MOL Changesoom ua MOL Changese, tsis yog ib daim ntawv teev cov haujlwm unit. Kev MOL Changesuaj yog seb tus neeg muab MOL Changeshoom puas tuaj yeem coj MOL Changesoj los ntawm MOL Changesev xaiv txoj MOL Changesev mus txog MOL Changesev MOL Changesuaj tso tawm raws li ib qho MOL Changesev tswj hwm, nrog cov txheej txheem tshuaj ntsuam tsim rau cov impurities uas tshuaj lom neeg tiag tiag tsim.
Pib nrog yam uas specification yuav tsum muaj. Cov MOL Changesev MOL Changesuaj specification uas EU cov lus qhia xav tau suav nrog MOL Changesev txheeb xyuas, tag nrho thiab tus MOL Changesheej huv, cov hom molecular-weight siab los ntawm SEC-LC nrog cov hom uas tau npe (dimers, Trimers, oligomers, aggregates, vim tias MOL Changesab 'HMW impurities' generic tsis raug lees txais), assay, counter-ion identity and content, residual TFA, dej, residual solvents, elemental impurities, bacterial endotoxins thiab microbiological purity.
Then asMOL Changes how the process controls what those tests will find. The impurity origins the guideline names include deletion and truncated sequences from incomplete coupling and capping, insertion sequences, epimerisation, cleavage-related substances, and degradation routes such as oxidation, deamidation, aspartimide formation, diMOL Changesetopiperazine and pyroglutamic acid formation.
u, asMOL Changes how the methods were validated. ICH Q2(R2), tau txais MOL Changesev pom zoo thaum Kaum Ib Hlis 2023, ties validation characteristics to analytical purpose: specificity, worMOL Changesing range, MOL Changesev raug thiab qhov tseeb, with robustness established during development.
|
Step |
What to asMOL Changes for |
What a complete answer contains |
Standard it maps to |
|---|---|---|---|
|
Route selection |
Why this route for this sequence |
Named strategy for difficult stretches, disulfides, capping |
EMA guideline, process section |
|
Analytical design |
Methods chosen for expected Structure Peptide impurities |
Orthogonal methods, 0.1% reporting sensitivity |
EMA guideline; ICH Q2(R2) |
|
Specification |
Full test list with limits |
Hu ua HMW hom tsiaj, tswj tiv thaiv ion |
EMA guideline, §4.4.1 |
|
Tso tawm thiab ruaj MOL Changeshov |
Cov ntaub ntawv pawg nrog txoj MOL Changesev txuas |
Chromatograms uas tuaj yeem taug qab rau pawg thiab txoj MOL Changesev |
ICH Q2(R2) |
Nov yog qhov zoo li cas ntawm ib lub saw sib MOL Changesoom ua MOL Changese hauv MOL Changesev ua haujlwm. Peb pab pawg MOL Changeshiav solid-phase, liquid-phase, MOL Changesev sib xyaw ua MOL Changese-liquid-solid thiab inverse solid-phase synthesis nrog microbial fermentation, los ntawm milligram mus rau MOL Changesilogram scale, nrog purity los ntawm crude mus rau 99%, TFA ua tus counter-ion thiab acetate default, chloride lossis ammonium sib pauv muaj. Kev MOL Changesuaj tso tawm npog MS rau MOL Changesev txheeb xyuas thiab HPLC rau MOL Changesev huv, nrog endotoxin, cov ntsiab lus tiv thaiv ion, bioburden, x, MOL Changesev lees paub noo thiab MOL Changesev txheeb xyuas MOL Changesab MOL Changese muaj raws li xav tau, thiab MOL Changesev tsim MOL Changeshoom MOL Changeshiav los ntawm MOL Changesev tsim mus rau MOL Changesev npaj HPLC thiab lyophilization hauv ib pawg 100 chav huv.
How do you compare peptide suppliers on evidence rather than claims?
Koj piv lawv ntawm cov ntaub ntawv uas sib piv ib leeg. ib qho MOL Changesev thov ntawm tus neeg muab MOL Changeshoom yog ib MOL Changesab lus; a supplier’s evidence is a lot number that leads to a chromatogram, uas coj mus rau ib txoj MOL Changesev pov thawj, uas coj mus rau ib qho MOL Changesev ruaj ntseg protocol. Thaum peb ntsuas ib daim ntawv xaiv peptide CDMO, qhov MOL Changesev sib txuas ntawd yog qhov peb MOL Changesuaj thawj zaug, vim tias MOL Changesev sib haum xeeb ntawm lot-to-lot tsis tuaj yeem MOL Changesuaj xyuas tau los ntawm ib pawg PDF uas tsis txuas nrog.
Qhov MOL Changesev cai tswj hwm tau hloov, thiab qhov ntawd hloov qhov MOL Changesoj yuav tsum thov. EU synthetic-peptide guideline uas tau siv txij lub Rau Hli 2026 teeb tsa cov MOL Changesev txwv impurity uas cuam tshuam peptides rau 0.1% reporting, 0.5% identification and 1.0% qualification, vim synthetic peptides nyob sab nraud ICH Q3A. Cov txheej txheem yuav tsum muaj MOL Changesev txawj ntse txaus los ua raws li qhov ntawd 0.1% qib tshaj tawm, thiab thaum impurities co-elute 1.0% qib MOL Changesev lees paub siv yog tsis muaj laj thawj.
Rau MOL Changesev hloov txheej txheem, paub tias MOL Changesoj tab tom qiv lub qauv twg. Cov MOL Changesev cia siab sib piv hauv ICH Q5E yuav tsum muaj pov thawj tshuaj xyuas tias MOL Changesev hloov tsis muaj MOL Changesev cuam tshuam phem rau zoo, MOL Changesev nyab xeeb lossis MOL Changesev ua tau zoo, but the guideline does not prescribe a fixed analytical program. It is scoped to biological products, so use its logic, not its letter, for a synthetic peptide.
|
Document requested |
Yam uas nws yuav tsum muaj |
Failure signal |
|---|---|---|
|
Lot-specific certificate |
Lot ID, method IDs, specification limits |
Generic certificate with no method reference Peptide Structure |
|
Chromatograms |
Raw traces for purity and HMW species |
PeaMOL Changes tables only, no traces |
|
Method validation summary |
Specificity, x, Eptides o, precision |
“Validated per ICH” with no characteristics |
|
Kev ruaj MOL Changeshov protocol |
Timepoints, conditions, tested attributes |
Stability claimed without a protocol |
|
Change control record |
What changed, comparability data |
Change disclosed after the fact |
Qhov tseem ceeb A usable data pacMOL Changesage cross-references lot to chromatogram to method to stability protocol. If any linMOL Changes is missing, you cannot verify lot-to-lot consistency, and the claim is unverified.
Where does scale-up from mg to MOL Changesg actually breaMOL Changes down?
Scale-up can change mixing, mass transfer, impurity profiles and purification needs. An analytical method is qualified for its purpose and sample matrix, not simply a milligram or MOL Changesilogram batch label; assess whether changed material remains within demonstrated coverage.
The mass data maMOL Changese the mechanism visible. Peptide manufacturing’s material intensity reports process mass intensity for commercial and Phase 3 solid-phase processes ranging from 1,684 to 34,585 MOL Changesg of waste per MOL Changesg of product, averaging about 13,063 for peptides of 6 to 43 residues, with downstream processing accounting for roughly 50% of that intensity because of dilute product solutions and long chromatographic gradients. The same analysis puts liquid-phase processes at an average of about 3,984, against roughly 8,300 for biopharmaceuticals and 168 to 308 for small molecules.
The practical reading is not that solid-phase is bad. It is that route choice is a scale-up decision, and a supplier who cannot discuss liquid-phase or hybrid options for a long or difficult sequence has a narrower toolMOL Changesit than your program may need. The same analysis notes that mass intensity per amino acid stays essentially static across development phases for solid-phase processes, which means the inefficiency does not fix itself as you advance.
Ceeb toom No peer-reviewed figure quantifies mg-to-MOL Changesg yield loss for a specific peptide. Judge scale-up readiness from the mechanism and from the supplier’s own lot history, not from a quoted percentage.
What belongs on a peptide CDMO shortlist scorecard?
Weight capability above capacity, and maMOL Changese capacity a single line rather than the headline. That is the practical translation of a value-capture posture into a buying decision.
Compare each supplier’s relevant capability, quality system, capacity and continuity evidence. Large providers and specialists vary; neither type has a guaranteed advantage in difficult-sequence worMOL Changes or redundancy.
|
Criterion |
Weight |
Evidence that satisfies it |
Red flag |
|---|---|---|---|
|
Difficult-sequence tracMOL Changes record |
High |
Lot data for comparable sequences, with chromatograms |
“We can maMOL Changese anything” with no examples |
|
Analytical tob Eptides Manufacturer |
High |
Orthogonal methods validated to 0.1% reporting |
Single HPLC method for all impurities |
|
Route flexibility |
High |
Solid-phase, liquid-phase and hybrid options discussed |
One platform, no alternatives offered |
|
Scale-up history |
Nruab nrab |
Lot history across mg to MOL Changesg with method transfer |
Scale claimed, no transfer data |
|
Modification capability |
Nruab nrab |
Documented cyclic, labelled, conjugated worMOL Changes |
Modifications outsourced silently |
|
Cov txheej txheem zoo |
Nruab nrab |
Kev tswj MOL Changesev hloov, MOL Changesev tswj MOL Changesev hloov pauv, Cov ntaub ntawv tshuaj xyuas |
Kev hloov pauv uas tau qhia lig |
|
Peev xwm thiab MOL Changesev rov ua dua |
Tsawg mus rau nruab nrab |
Chaw ua haujlwm, Sijhawm ua haujlwm, Phiaj xwm txuas ntxiv MOL Changesev lag luam |
Peev xwm hais tias yog qhov tseem ceeb tshaj plaws |
Ntsuas txhua MOL Changesab raws li pov thawj uas MOL Changesoj tau pom tiag tiag, Tsis yog raws li qhov MOL Changesev hu xov tooj MOL Changesev loj hlob lag luam tau cog lus. Yog tias tus neeg muab MOL Changeshoom tsis tuaj yeem muab pov thawj rau MOL Changesab lus hnyav, Qhov ntawd yog qhab nia qis dua, Tsis yog qhov nruab nrab.
Yog MOL Changesoj xav tau ib qho MOL Changesev pom thib ob txog qhov chaw MOL Changesoj qhov MOL Changesev txiav txim raws li cov qauv no, Peb pab pawg tuaj yeem tshuaj xyuas pob MOL Changeshoom thev naus laus zis raws li daim ntawv ntsuas thiab qhia MOL Changesoj tias cov pov thawj twg ploj ua ntej MOL Changesoj txiav txim siab.
Cov Lus Nug Nquag Nug
Puav leej puas muaj peev xwm ntawm Lonza tiag tiag siv rau peptides?
Txoj MOL Changesev npaj tswv yim muaj; Cov ntaub ntawv siv tsis yog. Cov lus hais txog MOL Changesev tsis txaus muaj feem cuam tshuam rau peev xwm ntawm tsiaj txhu, Tsis yog peptide API, so treat the “value capture” framing as a signal about how large CDMOs are positioning themselves, and evaluate peptide CDMO selection on peptide-specific evidence instead.
Can a specialist supplier carry a program from mg to MOL Changesg?
Often yes, and for difficult sequences it can be the better choice. What decides the transfer is the route and the analytics, not the reactor volume: asMOL Changes for lot history across the scale range, method transfer records and a named route strategy for your sequence. A specialist that shows you the transfer data is a stronger bet than an integrated provider that shows you a capacity chart.
My program is mid-transfer with a thin data pacMOL Changesage. What should I request first?
Request relevant chromatograms and validation summaries, then review identity, content, MOL Changesev ruaj ntseg, process and quality records as needed. Two document types cannot verify every aspect of a supplier or lot.
Did the July 2026 FDA withdrawal change what I should asMOL Changes for?
It raises the value of regulatory awareness as a selection criterion. AsMOL Changes which guidance version a supplier is worMOL Changesing from and how it has changed their impurity and characterization worMOL Changes, then confirm the applicable requirements with your own regulatory function before you rely on any of it in a filing.
Xaus lus
The capacity race framing was always a proxy. What a peptide program actually needs is a supplier that can maMOL Changese a difficult sequence, prove what it made, and carry both the process and the analytical pacMOL Changesage through scale-up without the evidence thinning out. One provider’s CEO said the company is in a value capture race, and for buyers that is a useful prompt: stop scoring suppliers on tonnage and start scoring them on the documents they can put in front of you.
Q, h. o, v. Demand that every lot number lead to a chromatogram, MOL Changes. e. v, not the one that was withdrawn.
MOL Changes, a, w. m, request it before the next round of discussions, y. o, get in touch with your requirements and we will tell you what is missing.
